The study, published Jan. 30 in Cureus, evaluated incidents of prostate cancer between January 2010 and December 2019 in patients with and without a history of C. difficile infection. A total of 79,226 patients were identified and separated into infected and control groups and subsequently matched by antibiotic treatment.
In the C. difficile group, 1.62 percent developed prostate cancer, while 3.95 percent developed prostate cancer in the control group.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
